創新醫療(002173.SZ):2020年度預虧2.8億元-3.8億元
格隆匯1月19日丨創新醫療(002173.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨虧損2.8億元-3.8億元,上年同期虧損11.5億元;扣除非經常性損益後的淨虧損2.5億元-3.5億元,上年同期虧損10.495億元;基本每股虧損0.62元-0.84元。業績變動原因如下
1、公司根據收到的遠程事件訴訟判決書結合考慮未判決的相關訴訟,共補提相關利息0.43億元;
2、由於疫情影響,康華醫院和明珠醫院經營情況未達預期,公司共計提商譽減值準備1.27億元,其中對康華醫院計提商譽減值準備1.07億元,對明珠醫院計提商譽減值準備0.2億元;
3、由於疫情影響,公司結合今年的經營業績以及未來的經營形勢判斷,將建華醫院前期確認的遞延所得税全部衝回,共計影響本期利潤0.48億元;
4、由於疫情影響,建華醫院和福恬醫院第四季度經營繼續虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.